News Sentiment

PRTA sentiment intelligence

Prothena Corporation plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.24 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.6% over one week, +12.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Trading the Move, Not the Narrative: (PRTA) Edition

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -4.6% Price reacting lower
Trend fit Trend inactive 12.0% over four weeks
Fair value -52.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Market source 9
TradingKey 8
Stock Titan 6
Stock Traders Daily 3
AD HOC NEWS 2
Finviz 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 19
Analyst action 3
Deals and strategy 2
Regulatory and legal 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Stock Traders Daily Direct company coverage

Trading the Move, Not the Narrative: (PRTA) Edition

This article analyzes Prothena Corporation Plc (NASDAQ: PRTA), highlighting weak near-term sentiment but strong mid- and long-term outlooks, suggesting potential shifts. It details sophisticated AI-driven trading strategies including position, momentum breakout, and risk hedging,

Tone
Negative 38/100
Event
Market update
Published
09 Jul 2026 12:02
Source
Stock Traders Daily
AD HOC NEWS Direct company coverage

Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens

Prothena Corp plc, a clinical-stage biotechnology company, is updating investors on its pipeline progress in neurodegenerative diseases, particularly Alzheimer's and related disorders. The company specializes in developing therapies that target protein misfolding and is listed on

Tone
Positive 72/100
Event
Analyst action
Published
07 Jul 2026 14:40
Source
AD HOC NEWS
TradingView Direct company coverage

Price to sales forward of Prothena Corporation plc – NASDAQ:PRTA

This article provides a brief snapshot of the "Price to sales forward" for Prothena Corporation plc (NASDAQ: PRTA) as found on TradingView. It indicates that the market was closed at the time the data was accessed, and no trades were recorded for this specific metric. The content

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 12:39
Source
TradingView
Barchart.com Direct company coverage

AL Amyloidosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda

DelveInsight's "AL Amyloidosis Pipeline Insight, 2026" report details over 10 companies developing 10+ therapies for AL Amyloidosis, covering clinical trials, mechanisms of action, and FDA approvals. Key developments include orphan drug designation for Attralus, Inc.'s zamubafusp

Tone
Negative 30/100
Event
Regulatory and legal
Published
01 Jul 2026 12:09
Source
Barchart.com
Finviz Direct company coverage

PRTA - Prothena Corp Plc Options

This article provides a detailed financial overview of Prothena Corp Plc (PRTA), including its stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's market capitalization, income, sales, and various valuation ratios, along

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 08:10
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of Prothena Corporation plc – NASDAQ:PRTA

This article provides financial data, specifically the price-to-earnings forward ratio, for Prothena Corporation plc (NASDAQ:PRTA). It is a brief data point from TradingView's financial overview for the biotechnology company. The content appears to be a stub or a data lookup resu

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 01:08
Source
TradingView
Stock Traders Daily Direct company coverage

(PRTA) Volatility Zones as Tactical Triggers

This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with spe

Tone
Positive 74/100
Event
Market update
Published
28 Jun 2026 11:08
Source
Stock Traders Daily
TradingView Direct company coverage

Price to sales forward of Prothena Corp. Plc – MUN:0PT

This article displays the "Price to sales forward" metric for Prothena Corp. Plc (MUN:0PT). It presents the period, value, change, and change percentage for this financial indicator. The content largely consists of a placeholder table for financial data and navigation elements.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Prothena Corporation plc – NASDAQ:PRTA

This page from TradingView provides financial information for Prothena Corporation plc (NASDAQ: PRTA). It specifically highlights the company's price to book forward metric, offering a snapshot of its financial valuation. The content focuses on market data and financial tools ava

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 16:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA

This article provides the enterprise value to revenue forward for Prothena Corporation plc (NASDAQ:PRTA). It lists the stock on the Nasdaq Stock Market and includes general information about its financial metrics. The original content appears to be a stub or a section of a larger

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 10:08
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA

This article provides financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBIT forward. It presents this metric in a table format, showing the period, value, change, and percentage change. The content appears to be a financ

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 09:08
Source
TradingView
TradingView Direct company coverage

Price to book forward of Prothena Corp. Plc – MUN:0PT

This article provides financial data for Prothena Corp. Plc (MUN:0PT), specifically focusing on its "Price to book forward" metric. The content highlights the company's financial overview on the Munich Stock Exchange, indicating market status and data source information.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 05:08
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Prothena Corporation plc – NASDAQ:PRTA

This article provides current financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBITDA forward metric. The information is presented through TradingView, a financial platform offering various market tools and data. The pag

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 00:40
Source
TradingView
Ad-hoc-news.de Direct company coverage

Prothena Corp, Parkinson antibody program draws attention for the stock

Prothena Corp (PRTA) is gaining investor attention due to its Parkinson's disease antibody, prasinezumab, developed in partnership with Roche. The company is focused on neurodegenerative diseases, and analysts are closely watching upcoming clinical milestones and the competitive

Tone
Positive 67/100
Event
Deals and strategy
Published
26 Jun 2026 15:40
Source
Ad-hoc-news.de
TradingView Direct company coverage

Prothena Corp. Plc Actuals & Estimates (NASDAQ:PRTA)

This article provides an overview of Prothena Corporation plc (NASDAQ: PRTA) stock, including its current price, market capitalization, and analyst forecasts. It details financial performance metrics like earnings per share and revenue for past quarters, and offers information on

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:40
Source
TradingView
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Financial Health: Profitability & Balance Sheet Analysis

Prothena Corporation PLC (PRTA) has a strong financial score of 9.21, ranking 10th in its industry, indicating robust financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 1706.36% to $51.08 million and a net profit

Tone
Positive 71/100
Event
Earnings
Published
25 Jun 2026 02:40
Source
TradingKey
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Prothena Corporation PLC (PRTA), detailing its support and resistance levels, price momentum score, and various technical indicator and moving average signals. As of June 26, 2026, PRTA has a price momentum score of 6.29, trading betw

Tone
Positive 62/100
Event
Market update
Published
24 Jun 2026 15:40
Source
TradingKey
富途牛牛 Direct company coverage

Prothena Corporation Plc (NASDAQ:PRTA) About To Shift From Loss To Profit

The article discusses Prothena Corporation Plc (NASDAQ:PRTA) and its anticipated shift from a loss to a profit. It examines the company's historical earnings, future growth prospects, and the factors contributing to its expected profitability. This transition is highlighted as a

Tone
Positive 77/100
Event
Earnings
Published
24 Jun 2026 01:41
Source
富途牛牛
AD HOC NEWS Direct company coverage

Prothena Corp plc strategy in focus, shares watched against biotech peers

Prothena Corp plc (PRTA) is a late-stage neuroscience biotech company listed on Nasdaq, specializing in antibody therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, and amyloidosis. The company's strategy involves partnerships with major pharmaceutical firms s

Tone
Positive 67/100
Event
Market update
Published
22 Jun 2026 18:09
Source
AD HOC NEWS
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Prothena Corporation PLC (PRTA), detailing its earnings forecast score, average price target, and analyst ratings. It highlights that the company's current earnings forecast score is 6.67, ranking 327 out of 389 in its industry, with

Tone
Positive 59/100
Event
Earnings
Published
18 Jun 2026 12:10
Source
TradingKey
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Prothena Corporation PLC (PRTA). It indicates that relevant business segment and regional revenue data have not yet been disclosed by the company. The page displays basic stock information including market cap and curr

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:18
Source
TradingKey
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Prothena Corporation PLC's (PRTA) dividend and stock split history, noting that no dividend data is available for the past five years and no stock split data is recorded. It highlights the company's current stock price, market capitalization,

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 06:18
Source
TradingKey
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Prothena Corporation PLC (PRTA), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholder types and provides data on institutional shareholding over vari

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:18
Source
TradingKey
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.53 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.18, and states that relevant data for P/B, P/S, and P/CF ra

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
TradingKey
TradingKey Direct company coverage

Prothena Corporation PLC (PRTA) Institutional Confidence

Prothena Corporation PLC (PRTA) has a strong institutional confidence score of 10.00, ranking first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 96.24%, an increase of 19.52% quarter-over-quarter. Fidelity Management & R

Tone
Positive 71/100
Event
Market update
Published
16 Jun 2026 22:40
Source
TradingKey
Stock Traders Daily Direct company coverage

(PRTA) Price Dynamics and Execution-Aware Positioning

This article provides an analysis of Prothena Corporation Plc (NASDAQ: PRTA) using AI models to determine price dynamics and optimal positioning. It highlights weak near-term sentiment but strong long-term prospects, offering distinct institutional trading strategies for differen

Tone
Negative 39/100
Event
Market update
Published
06 Jun 2026 08:10
Source
Stock Traders Daily